In this context, the present review seeks to address a critical question: How do etiology-specific alterations in NRF2 signaling dictate the efficacy and therapeutic window of NRF2-targeted treatments across the spectrum of CKD? The gene discussed is NFE2L2; the disease is chronic kidney disease.